Percutaneous gas-line

Information

  • Patent Grant
  • 7887478
  • Patent Number
    7,887,478
  • Date Filed
    Thursday, October 28, 2004
    20 years ago
  • Date Issued
    Tuesday, February 15, 2011
    13 years ago
Abstract
A percutaneous gas-line (10) for a medical device (14). The gas-line including a first gas-line part (10a) and a second gas-line part (10b). The first gas-line part (10a) is adapted to be wholly implanted in a patient and has a first end (10a′) adapted for sealing connection to the medical device (14) and a second end (10a″) with a connection fitting (20). The second gas-line part (10b) is adapted to be part-implanted and part-external and has a first (external) end (10b′) adapted for sealing connection to an external driver (12) and a second (implanted) end (10b″) adapted for removable sealing connection with the connection fitting (20) on the second end (10a″) of the first gas-line part (10a).
Description
FIELD OF THE INVENTION

The present invention relates generally to a heart assist device, system and method and more particularly to a percutaneous gas-line for an implanted medical device such as a left ventricular assist device (LVAD), or counter-pulsation or co-pulsation heart assist device and to a heart assist device incorporating such a gas-line.


BACKGROUND OF THE INVENTION

International PCT patent application no. PCT/US00/22992 (WO 01/13974) discloses a gas-driven device heart assist device, that requires a percutaneous positioned gas-line.


U.S. Pat. No. 6,132,363 discloses a percutaneous access device (PAD) system, that allows both gas and electrical transmission, that utilises an intermediary connector piece that has the patient's own fibroblasts cultured onto the hub of the PAD. This has the proposed advantage of reducing infection. However, its disadvantages include its large size, inflexible nature, and that implantation is a two or three staged procedure. Specifically, implantation involves making a large skin biopsy, isolating the fibroblasts from the biopsy and growing the cells, then culturing them onto the device (which is a 10 day process). When the culturing process has been completed, the PAD can be implanted in the abdomen, and then the counterpulsation device implanted.


It is an object of the present invention to provide an improved percutaneous gas-line that, at least in preferred embodiments, requires no antecedent preparation and has a low risk profile for infection, but which allows remedial action to be taken in the event that gas-line infection occurs. It is well known that infection related to percutaneous lines in general is influenced by the diameter, flexibility and nature of the material. As such, a smaller, more flexible and soft (particularly Silicone) material are most advantageous in reducing infection—this is in direct contrast to the PAD as disclosed above.


It is a further object to provide a gas line for a heart assist device which gas line incorporates an ECG lead to provide for monitoring of the heart internally of the patient's body to control the operation of the heart assist device.


SUMMARY OF THE INVENTION

Accordingly, in a first aspect, the present invention provides a percutaneous gas-line for a medical device, the gas-line including:


a first gas-line part adapted to be wholly implanted in a patient and having a first end adapted for sealing connection to the medical device and a second end with a connection fitting; and


a second gas-line part adapted to be part-implanted and part-external and having a first (external) end adapted for sealing connection to an external driver and a second (implanted) end adapted for removable sealing connection with the connection fitting on the second end of the first gas-line part.


The second gas-line part is preferably further adapted to be removable, for replacement, in the presence of persistent exit-site infection or damage to the external part.


The medical device is preferably a heart assist device, more preferably a left ventricular assist device (LVAD), or a counter-pulsation or co-pulsation heart assist device.


The first (external) end of the second gas line is preferably removably connected to the external driver.


In preferred embodiments of the invention, an ECG lead adapted to connect a patient's heart with a control system for a heart assist device utilising the gas line according to this invention is incorporated into the first gas line part and/or the second gas line part.


The second gas-line part is preferably constructed to have a minimal outside diameter, more preferably less than 7 mm, and has high flexibility and a resistance to kinking or collapsing. The second gas-line part is preferably made of a soft biocompatible, biostable material, such as silicone 45-65A durometer. This gas-line part may be wire-wound internally to allow thin wall and kink/collapse resistance.


The connection fitting is preferably a Luer-lock or similar gas-tight fitting.


The first and/or second gas-line parts preferably have a fluffy polyester, or similar, collar over about a short section (eg. 20-50 mm) of their implanted length. The collar being adapted to encourage sub-cuateous tissue ingrowth to help reduce any movement of the gas-line in situ—the collar is preferably at least 20 mm from the percutaneous exit site.


In a second aspect, the present invention provides a method of providing heart assistance to a patient using a percutaneous gas-line having a first gas-line part, adapted to be wholly implanted, and a second gas-line part, adapted to be part implanted and part external, connected to the first gas-line part, the method including the steps of:


(1) recognising a persistent exit-site infection;


(2) disconnecting the second gas-line part from the first gas-line part;


(3) removing the second gas-line part from the patient; and


(4) connecting a sterile second gas-line part to the first gas-line part


wherein the fresh second gas-line part is inserted through a fresh exit-site that is remote to the infected exit-site.


It will also be understood by persons skilled in the art that the fresh second gas-line part is inserted through an implant tunnel that is also substantially remote from the existing implant tunnel.


Alternatively, after step (3), the first gas-line part (and the implanted ECG cable, if it is attached to a corresponding interconnect cable associated with the second gas-line part) is sealed and wounds are closed to allow healing to occur (which may include prolonged treatment with antibiotics), at this time the device is non-functional, but can, at a later time, be made functional by re-implanting the second part and sealing attaching it to the first part.


In a third aspect, the present invention provides a gas line for connecting an inflatable heart assist actuator to a driver therefore, the gas line having a first end operatively connected to the inflatable actuator and a second end connectable, directly or indirectly through an extension gas line, to the driver for the heart assist actuator, the gas line having attached to it an ECG lead, the ECG lead having a first end adapted for connection to the heart of a patient and a second end adapted for connection to the driver or a controller for the driver, the attachment between the gas lead and the ECG lead being such that they are adapted to pass through the skin of a patient as a single element.





BRIEF DESCRIPTION OF THE DRAWINGS

A preferred embodiment of the invention will now be described, by way of an example only, with reference to the accompanying drawing in which:



FIG. 1 is a schematic view of a percutaneous gas-line according to an embodiment of the invention, connected between an implanted heart assist device and an external driver.



FIG. 2 is a schematic view of a percutaneous gas-line according to a second embodiment of the invention, connected between an implanted heart assist device and an external driver and in which an ECG cable is incorporated into the gas line.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT


FIG. 1 shows a percutaneous gas-line 10 according to a first embodiment of the invention. The gas-line 10 has a first part 10a and a second part 10b.


The gas-line 10 connects an external gas driver 12 to a left ventricle heart assist device 14, which is positioned around a patient's aorta 16. The heart assist device 14 comprises a balloon (not shown), a bushing (not shown), and a wrap 18 to hold the balloon in position around the aorta 16.


The first part 10a of the gas-line 10 has a first end 10a′ sealingly connected to the bushing and in gas communication with the balloon. The first part 10a of the gas-line 10 also has a second end 1Oa″ with a gas-tight Leur-lock fitting 20 thereon. The first part 10a of the gas-line 10 is made of a polyurethane-polysiloxane block co-polymer similar to that used to form the balloon and bushing.


The second part of 10b of the gas-line 10 is shown positioned percutaneous through an exit site 22. The external/un-implanted portion of the second part 10b has a first end l0b′ that is connected to the external driver 12 with a gas tight but removable fitting. The second gas-line part 10b also has a second end 10b″ connected to the second end 10a″ of the first part 10a at the Luer fitting 20, such that the first gas-line part 10a and the second gas-line part 10b extend from the Luer fitting 20 in a substantially coaxial or straight configuration as shown. The implanted portion of the second part 10b also has about it a polyester collar 24 for anchoring the gas-line subcutaneously approx 20-50 mm from an exit site 22.


The second part 10b can be made of a different material to the first part 10a. It is preferably made of silicone or silicone-polyurethane co-polymer. The second part 10b can also be more flexible than the first part 10a and can be wire-wound.


In the event that the external part of the gas-line 10 is damaged in every-day use, or if a persistent infection develops at the exit site 22, then the second part 10b is able to be exchanged for a fresh/new (sterilised) second part 10b which is brought out of the patient via a new exit-site 22 (see phantom lines). As this can be done without need to replace the whole heart assist device arrangement, the surgery is minimal. More 25 particularly, the surgery only involves a small incision (not shown) over the subcutaneous connection, undoing of the connection of the Luer lock 20, and removal ofthe second part 10b. A new exit-site 22 is then made, and a new second part 10b tunnelled through to the first incision for reconnection of the first 10a and (new) second 10b parts. Ifthe infection has travelled up the original second gas line part 10b then the fresh second gas-line part is 30 inserted through an implant tunnel that is also substantially remote from the existing implant tunnel.



FIG. 2 shows a percutaneous gas-line 10′ according to a second embodiment of the invention. Like features to those of the first embodiment are indicated with like reference numerals in the second embodiment.


The gas-line 10′ includes a first part (implanted) epicardial ECG lead 26, a sleeve 28 and a second part (percutaneous) ECG lead 30. The lead 26 enters the sleeve 28, which is connected between the first and second parts of the gas line 10a and 10b. The sleeve 28 has an electrical connector therein (not shown) that connects the lead 26 to an extension of the lead 30. The lead parts 26 and 30 therefore advantageously provide direct communication of ECG signals from the patient's heart to the driver 12.


The lead 30 is connected to the driver 12 and is contained within the interior of the gas-line second part 10b. Alternatively, the lead 30 can be glued to the exterior of the gas-line second part 10b. In either case, only a single exit site 22 is required, thereby minimising infection risk and patient discomfort.


It will be appreciated by the persons skilled in the art that numerous variations and/or modifications can be made to the invention as shown in the specific embodiment without departing from the spirit or scope of the invention as broadly defined. For example, the blood displacing devices are described above in relation to extra-aortic counter-pulsation but also suitable for intra aortic counter-pulsation devices, co-pulsation devices, or pneumatic driven LVADs.

Claims
  • 1. A percutaneous gas line for an implantable medical device, the gas line comprising: (a) a first gas line comprising a first end configured to be sealably coupled to the medical device and a second end;(b) a connection fitting configured to be disposed entirely within a patient's body, wherein the connection fitting is configured to be sealably coupled to the second end of the first gas line; and(c) a second gas line comprising: (i) a first end configured to be sealably and removably coupled to the connection fitting;(ii) a subcutaneous anchoring collar coupled around an outer surface of the second gas line along a length of the second gas line, wherein the collar is positioned in spaced relationship with the first end of the second gas line such that the collar is configured to be disposed within the patient's body when the first end is coupled to the connection fitting; and(iii) an opening defined in the first end, wherein the opening is in communication with a lumen defined within the second gas line, wherein the opening is substantially coaxial with a longitudinal axis of the gas line.
  • 2. The percutaneous gas line of claim 1, further comprising an end portion defined between the first end of the second gas line and the subcutaneous anchoring collar, wherein the end portion extends from the connection fitting in a substantially coaxial configuration.
  • 3. The percutaneous gas line of claim 1, wherein the second gas line comprises a second end configured to be sealably and removably coupled to an external driver.
  • 4. The percutaneous gas line of claim 1, further comprising an ECG lead incorporated into the first gas line or the second gas line, wherein the ECG lead comprises a first end configured to be coupled to a control system and a second end configured to be positioned within the patient's body.
  • 5. The percutaneous gas line of claim 1, wherein the subcutaneous anchoring collar comprises a fluffy polyester.
  • 6. The percutaneous gas line of claim 1, wherein the subcutaneous anchoring collar has a length ranging from about 20 mm to about 50 mm.
  • 7. The percutaneous gas line of claim 1, wherein the medical device comprises a heart assist device.
  • 8. The percutaneous gas line of claim 7, wherein the heart assist device comprises a wrap configured to be disposed around an aorta of the patient.
  • 9. The percutaneous gas line of claim 7, wherein the heart assist device is an inflatable heart assist actuator.
  • 10. The percutaneous gas line of claim 1, wherein the medical device comprises a left ventricular assist device.
  • 11. The percutaneous gas line of claim 1, wherein the connection fitting comprises a Luer-lock gas-tight fitting.
  • 12. The percutaneous gas line of claim 1, further comprising an ECG lead associated with the second gas line.
  • 13. The percutaneous gas line of claim 12, wherein the ECG lead is disposed within the second gas line.
  • 14. The percutaneous gas line of claim 12, wherein the ECG lead is coupled to an exterior portion of the second gas line.
  • 15. The percutaneous gas line of claim 12, wherein the ECG lead comprises a first part configured to be positioned within the patient's body and a second part associated with the second gas line.
Priority Claims (1)
Number Date Country Kind
2003906067 Oct 2003 AU national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/AU2004/001485 10/28/2004 WO 00 4/28/2006
Publishing Document Publishing Date Country Kind
WO2005/042082 5/12/2005 WO A
US Referenced Citations (100)
Number Name Date Kind
0283660 Reed Aug 1883 A
0929571 Dubied Jul 1909 A
1576397 Yanagi Jul 1925 A
1719316 Appleton Jul 1929 A
3467077 Cohen Sep 1969 A
3552383 Krueger et al. Jan 1971 A
3597766 Buck Aug 1971 A
4014318 Dockum et al. Mar 1977 A
4051840 Kantrowitz et al. Oct 1977 A
4176411 Runge Dec 1979 A
4195623 Zeff et al. Apr 1980 A
4236482 Gingerich et al. Dec 1980 A
4256094 Kapp Mar 1981 A
4277706 Isaacson Jul 1981 A
4304225 Freeman Dec 1981 A
4454891 Dreibelbis et al. Jun 1984 A
4457673 Conley et al. Jul 1984 A
4459977 Pizon et al. Jul 1984 A
4515587 Schiff May 1985 A
4583523 Kleinke et al. Apr 1986 A
4594731 Lewkowicz Jun 1986 A
4630597 Kantrowitz et al. Dec 1986 A
4676482 Reece et al. Jun 1987 A
4697574 Karcher et al. Oct 1987 A
4763646 Lekholm Aug 1988 A
4771765 Choy et al. Sep 1988 A
4809676 Freeman Mar 1989 A
4813952 Khalafalla Mar 1989 A
4822357 Forster et al. Apr 1989 A
4881939 Newman Nov 1989 A
4957477 Lundback Sep 1990 A
4979936 Stephenson et al. Dec 1990 A
5089017 Young et al. Feb 1992 A
5197980 Gorahkov et al. Mar 1993 A
5205810 Guiraudon et al. Apr 1993 A
5222980 Gealow Jun 1993 A
5267940 Moulder Dec 1993 A
5273518 Lee Dec 1993 A
5290249 Foster et al. Mar 1994 A
5300111 Panton et al. Apr 1994 A
5337752 Reeves Aug 1994 A
5344385 Buck et al. Sep 1994 A
5360445 Goldowsky Nov 1994 A
5372573 Habib Dec 1994 A
5429584 Chiu Jul 1995 A
5447523 Schaldach Sep 1995 A
5453076 Kiyota et al. Sep 1995 A
5511551 Sano et al. Apr 1996 A
5554177 Kieval et al. Sep 1996 A
5569156 Mussivand Oct 1996 A
5593414 Shipp et al. Jan 1997 A
5607378 Winston Mar 1997 A
5647380 Campbell et al. Jul 1997 A
5722930 Larson, Jr. et al. Mar 1998 A
5792195 Carlson et al. Aug 1998 A
5814012 Fleenor et al. Sep 1998 A
5820542 Dobak, III et al. Oct 1998 A
5827171 Dobak, III et al. Oct 1998 A
5843170 Ahn Dec 1998 A
5975140 Lin Nov 1999 A
5980488 Heilman et al. Nov 1999 A
6030336 Franchi Feb 2000 A
6045496 Pacella et al. Apr 2000 A
6066085 Heilman et al. May 2000 A
6132363 Freed et al. Oct 2000 A
6132636 Singh et al. Oct 2000 A
6210318 Lederman Apr 2001 B1
6226843 Crainich May 2001 B1
6251061 Hastings et al. Jun 2001 B1
6432039 Wardle Aug 2002 B1
6471633 Freed Oct 2002 B1
6553263 Meadows et al. Apr 2003 B1
6572534 Milbocker et al. Jun 2003 B1
6585635 Aldrich Jul 2003 B1
6616596 Milbocker Sep 2003 B1
6626821 Kung et al. Sep 2003 B1
6643548 Mai et al. Nov 2003 B1
6808483 Ortiz et al. Oct 2004 B1
6808484 Peters et al. Oct 2004 B1
6984201 Khaghani et al. Jan 2006 B2
7169109 Jansen et al. Jan 2007 B2
7360558 Peters et al. Dec 2007 B1
7347811 Peters et al. Mar 2008 B2
7357771 Peters et al. Apr 2008 B2
7513864 Kantrowitz et al. Apr 2009 B2
7740575 Peters et al. Jun 2010 B2
7765003 Miller et al. Aug 2010 B2
20030105497 Zhu et al. Jun 2003 A1
20040073080 Peters et al. Apr 2004 A1
20040097783 Peters et al. May 2004 A1
20040097784 Peters et al. May 2004 A1
20040147803 Hegde et al. Jul 2004 A1
20060052866 Gilles et al. Mar 2006 A1
20070093684 Peters et al. Apr 2007 A1
20070129796 Miller Jun 2007 A1
20070135677 Miller et al. Jun 2007 A1
20070167898 Peters et al. Jul 2007 A1
20080027270 Peters et al. Jan 2008 A1
20080139873 Peters et al. Jun 2008 A1
20080167515 Peters et al. Jul 2008 A1
Foreign Referenced Citations (44)
Number Date Country
2003277983 Jun 2008 AU
1541311 Nov 1966 DE
0080348 May 1988 EP
0363203 Apr 1990 EP
0216042 Mar 1991 EP
0601804 Jun 1994 EP
0364799 May 1995 EP
1129736 Sep 2001 EP
2458288 Jan 1981 FR
2645739 Oct 1990 FR
2767874 Mar 1999 FR
2422114 Apr 2008 GB
9-502376 Mar 1997 JP
9-503933 Apr 1997 JP
10-328297 Dec 1998 JP
H11-285529 Oct 1999 JP
2000-510006 Aug 2000 JP
WO 9208500 May 1992 WO
WO 9308874 May 1993 WO
WO 9505122 Feb 1995 WO
WO 9528127 Oct 1995 WO
WO 9740755 Nov 1997 WO
WO 9805289 Feb 1998 WO
WO 9814239 Apr 1998 WO
WO 9851367 Nov 1998 WO
WO 9902213 Jan 1999 WO
WO 9904833 Feb 1999 WO
WO 9945981 Sep 1999 WO
WO 00012168 Mar 2000 WO
WO 00076288 Dec 2000 WO
WO 0113974 Mar 2001 WO
WO 0183001 Nov 2001 WO
WO 02024254 Mar 2002 WO
WO 02024255 Mar 2002 WO
WO 02076305 Oct 2002 WO
WO 03011365 Feb 2003 WO
WO 03028787 Apr 2003 WO
WO 2004045677 Jun 2004 WO
WO 2005041783 May 2005 WO
WO 2005042063 May 2005 WO
WO 2005044338 May 2005 WO
WO 2005110512 Nov 2005 WO
WO 2008053469 May 2008 WO
WO 2008071223 Jun 2008 WO
Related Publications (1)
Number Date Country
20070021830 A1 Jan 2007 US